Metoprolol (generic), Toprol XL Newswire

Metoprolol (generic), Toprol XL Newswire

Comprehensive Real-Time News Feed for Metoprolol (generic), Toprol XL.

Results 1 - 20 of 22 in Metoprolol (generic), Toprol XL

  1. EPS for Aralez Pharmaceuticals Inc. (ARLZ) Expected At $-0.37; Harsco (HSC)'s Sentiment Is 1.31Read the original story w/Photo

    Friday Feb 9 | Hill Country Times

    Harsco Corporation provides industrial services and engineered products worldwide. The company has market cap of $1.26 billion.

    Comment?

  2. Heart Failure Drugs 2018 Global Market Expected to Grow at CAGR 10.46% and Forecast to 2022Read the original story w/Photo

    Jan 9, 2018 | SBWire

    The analysts forecast the global heart failure drugs market to grow at a CAGR of 10.46% during the period 2018-2022. The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease.

    Comment?

  3. Lannett shares jump 8% on news it will be exclusive distributor of beta-blocker Toprol-XLRead the original story w/Photo

    Dec 1, 2017 | MarketWatch

    "Metoprolol Succinate is a widely prescribed medication and will be an important addition to our cardiovascular product offering," Lannett Chief Executive Arthur Bedrosian said in a statment. Raymond James analyst Elliot Wilbur said the company is continuing a winning streak.

    Comment?

  4. 6 common medications that could be to blame for your weight gainRead the original story w/Photo

    Oct 16, 2017 | MSN Healthy Living

    There are sneaky things that cause weight gain that aren't food or exercise . One of them may be prescription medication.

    Comment?

  5. August 22, 2017, PNLR E-NewsletterRead the original story w/Photo

    Aug 21, 2017 | Trial

    The plaintiff alleged that a hospital was liable for its nurse's failure to adequately monitor a heart patient's vital signs, connect his external pacemaker, and notify a physician of his bradycardia. The jury awarded approximately $5.8 million.

    Comment?

  6. ARCA Biopharma Announces Completion of Enrolment for GENETIC-AF Phase ...Read the original story w/Photo

    Aug 15, 2017 | Drugs.com

    ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the completion of enrolment for GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial evaluating Gencaro as a potential genetically-targeted treatment for atrial fibrillation . ARCA expects to report top-line Phase 2B data late in the first quarter of 2018.

    Comment?

  7. ARCA biopharma Announces Completion Of Enrollment For GENETIC-AF Phase IIb Clinical TrialRead the original story

    Aug 15, 2017 | BioSpace

    ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the completion of enrollment for GENETIC-AF , a Phase 2B, double-blind, superiority clinical trial evaluating GencaroTM as a potential genetically-targeted treatment for atrial fibrillation . ARCA expects to report top-line Phase 2B data late in the first quarter of 2018.

    Comment?

  8. Aralez Pharmaceuticals' (ARLZ) CEO Adrian Adams on Q2 2017 Results - Earnings Call TranscriptRead the original story w/Photo

    Aug 9, 2017 | Seeking Alpha

    Greetings, and welcome to the Aralez Pharmaceuticals Second Quarter 2017 Earnings Conference Call. [Operator Instructions].

    Comment?

  9. ARCA biopharma Announces Genetic-Af Data And Safety Monitoring Board...Read the original story

    Aug 9, 2017 | BioSpace

    ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the GENETIC-AF trial Data and Safety Monitoring Board completed its pre-specified Phase 2B interim analysis. Based on its efficacy and safety review, the DSMB recommended completion of the Phase 2B trial with no changes to the trial design.

    Comment?

  10. Aralez Reports Second Quarter 2017 Financial ResultsRead the original story w/Photo

    Feb 5, 2016 | Canada NewsWire

    The Company also highlighted certain corporate and commercial updates. All figures are in U.S. dollars.

    Comment?

  11. Atrial Septal Defect Market Competitive Dynamics & Global Outlook 2024Read the original story w/Photo

    Aug 7, 2017 | SBWire

    Global Atrial Septal Defect Market: Outlook Atrial septal defect is one of the most common congenital cardiac diseases and usually affects women more than men. It is characterized by a hole or defect in the interatrial septum that separates the heart's two upper chambers, i.e., atria.

    Comment?

  12. Woman allegedly scammed via phoneRead the original story w/Photo

    Aug 7, 2017 | LaGrange Daily News

    An alleged telephone scam resulted in a woman losing $199 at the Tiny Treasure Learning Center approximately a month ago.

    Comment?

  13. Cardiovascular Disease Drug Market Research Report by Key Players Analysis 2023Read the original story w/Photo

    Aug 2, 2017 | SBWire

    Cardiovascular disease is a major cause of death in the U.S. and rest of the world. These diseases are primarily related with heart and blood vessels disorders, such asischemic heart disease, dyslipidemia, stroke, thrombosis, atherosclerosis, coronary artery diseases, peripheral artery disease and others.

    Comment?

  14. The 50 most dangerous drugsRead the original story w/Photo

    Jul 24, 2017 | WDBO-AM Orlando

    While overdose deaths from prescription opioids have nearly quadrupled since 1999, some of the most dangerous drugs don't require a prescription. Using data from the Food and Drug Administration for 2004 through 2015, HealthGrove looked at the 150 drugs that are involved in the highest number of adverse reactions and ranked them by the percent of these reactions classified as serious.

    Comment?

  15. ARCA biopharma Announces Database Lock For GENETIC-AF Phase IIB...Read the original story

    Jun 19, 2017 | BioSpace

    ARCA biopharma, Inc. , a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced database lock for the GENETIC-AF Phase 2B interim efficacy analysis, to be conducted by the trial Data Safety Monitoring Board . GENETIC-AF is a seamless design Phase 2B/3 clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation .

    Comment?

  16. Atrial Septal Defect: Market Competition, Value Chain Analysis and Forecast 2024Read the original story w/Photo

    Jun 12, 2017 | SBWire

    Global Atrial Septal Defect Market: Outlook Atrial septal defect is one of the most common congenital cardiac diseases and usually affects women more than men. It is characterized by a hole or defect in the interatrial septum that separates the heart's two upper chambers, i.e., atria.

    Comment?

  17. Atrial Septal Defect Market - Global Industry Analysis 2016: Research ReportRead the original story w/Photo

    Jun 9, 2017 | SBWire

    Global Atrial Septal Defect Market: Outlook Atrial septal defect is one of the most common congenital cardiac diseases and usually affects women more than men. It is characterized by a hole or defect in the interatrial septum that separates the heart's two upper chambers, i.e., atria.

    Comment?

  18. Due Diligence: Calculating the Regulatory Review Period for Patent Term ExtensionRead the original story w/Photo

    May 26, 2017 | JD Supra

    When applying for a patent term extension , due diligence matters. If an applicant did not act with due diligence during the testing phase or the approval phase, the time during which it failed to do so will be deducted from the PTE.

    Comment?

  19. Cardiovascular Disease Drug Market Estimated to Flourish by 2023Read the original story w/Photo

    May 10, 2017 | SBWire

    Cardiovascular disease is a major cause of death in the U.S. and rest of the world. These diseases are primarily related with heart and blood vessels disorders, such asischemic heart disease, dyslipidemia, stroke, thrombosis, atherosclerosis, coronary artery diseases, peripheral artery disease and others.

    Comment?

  20. Aralez Reports First Quarter 2017 Financial ResultsRead the original story

    May 8, 2017 | BioSpace

    In addition, we continue to implement our cost savings plan to further improve our cost structure and balance sheet to maximize and preserve our financial flexibility. Our updated financial guidance for 2017 reflects our commitment to reaching break-even on an Adjusted EBITDA basis this year.

    Comment?